SCHEMBL4867935

SCHEMBL4867935

COc1ccc(S(=O)(=O)NCC(=O)Nc2ccc(C)cc2C(O)c2c(F)cccc2F)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEP1B Q16820 2/20 0.49
F2 P00734 2/20 0.48
KMT2A Q03164 1/20 0.47
TMPRSS6 Q8IU80 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
BACE1 P56817 1/20 0.44
ALDH1A1 P00352 2/20 0.43
MAPK1 P28482 1/20 0.43
KAT6A Q92794 1/20 0.42
TSHR P16473 2/20 0.41
LMNA P02545 2/20 0.41
HTT P42858 1/20 0.41
MAPT P10636 2/20 0.41
OXTR P30559 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4867419 0.92 MEP1B (0.50) MEP1BF2KMT2ATMPRSS6ALDH1A1
SCHEMBL3247179 0.91 MEP1B (0.49) MEP1BF2KMT2ATMPRSS6NPSR1
SCHEMBL3246588 0.90 MEP1B (0.48) MEP1BF2KMT2ATMPRSS6ALDH1A1
SCHEMBL3244401 0.89 MEP1B (0.49) MEP1BF2KMT2ATMPRSS6SMN1; SMN2
SCHEMBL3256360 0.88 MEP1B (0.49) MEP1BF2KMT2ATMPRSS6NPSR1
SCHEMBL3250769 0.87 MEP1B (0.47) MEP1BF2KMT2ASMN1; SMN2BACE1
SCHEMBL4872053 0.87 MEP1B (0.47) MEP1BF2KMT2ATMPRSS6SMN1; SMN2
SCHEMBL3243662 0.86 MEP1B (0.46) MEP1BF2KMT2ATMPRSS6NPSR1
SCHEMBL3247448 0.85 TSHR (0.49) MEP1BF2KMT2ATMPRSS6SMN1; SMN2
SCHEMBL3253020 0.84 MEP1B (0.52) MEP1BF2KMT2ATMPRSS6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 MEP1B 1627/4885F2 4182/4885KMT2A 1181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.